Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
Merck & Company (MRK) Stock Price & Analysis
11,619 Followers
MRK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$97.22 - $134.63
Previous Close$125.77
Volume6.85M
Average Volume (3M)8.47M
Market Cap
$318.55B
Enterprise Value$347.21B
Total Cash (Recent Filing)$5.62B
Total Debt (Recent Filing)$34.22B
Price to Earnings (P/E)140.0
Beta0.16
Next Earnings
Jul 30, 2024EPS Estimate
$2.16Last Dividend Ex-Date
Jun 17, 2024Dividend Yield2.42%
Share Statistics
EPS (TTM)0.90
Shares Outstanding2,532,806,307
10 Day Avg. Volume8,283,382
30 Day Avg. Volume8,466,701
Standard Deviation0.06
R-Squared0.12
Alpha0.00807
Financial Highlights & Ratios
Price to Book (P/B)205.52
Price to Sales (P/S)5.51
Price to Cash Flow (P/CF)26.80
P/FCF Ratio33.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.65
Enterprise Value/Gross Profit7.89
Enterprise Value/Ebitda44.21
Forecast
1Y Price Target
$147.40Price Target Upside17.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Merck & Company News
PremiumPress Releases
Elanco Completes Sale of Aqua BusinessBulls Say, Bears Say
Bulls Say
Market ShareMRK believes Capvaxive can achieve majority market share in the adult pneumococcal vaccine market, which it projected will grow to ~$3bn.
Product LaunchStrong demand and building access could result in a strong Winrevair launch.
Vaccine ApprovalThe FDA approved MRK's Capvaxive (V116), a 21-valent adult-specific pneumococcal vaccine for the prevention of invasive disease and pneumonia in 18+ year olds.
Bears Say
Cost-EffectivenessNew economic analysis for V116 was not very helpful, with CDC models suggesting ~$270K per QALY in 50-64 year olds and deemed 'unacceptable.'
Market ShareChecks with management suggest declining share in public and private market for Vaxneuvance.
Regulatory ChallengesPatritumab Deruxtecan's complete response letter (CRL) delays entry into the 3L+ EGFR mutant NSCLC space and incrementally dragged on MRK's shares.
---
Ownership Overview
0.16% Insiders
22.29% Mutual Funds
20.90% Other Institutional Investors
56.65% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $97.22 and its highest was $134.63 in the past 12 months.
What is Merck & Company’s market cap?
Currently, no data Available
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Jul 30, 2024 which is in 9 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Apr 25, 2024. The company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.886 by $0.184.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.77 which represents an annual dividend yield of 2.42%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is $2.16.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,532,806,400 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $2.07 in its last earnings report, beating expectations of $1.886. Following the earnings report the stock price went up 2.931%.
Which hedge fund is a major shareholder of Merck & Company?
Among the largest hedge funds holding Merck & Company’s share is Fisher Asset Management LLC. It holds Merck & Company’s shares valued at 2B.
---
Merck & Company Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$147.40 (17.20% Upside)
$147.40 (17.20% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 90%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 490.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.87%
12-Months-Change
Fundamentals
Return on Equity
5.29%
Trailing 12-Months
Asset Growth
-1.81%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
---
MRK Company Deck
---
MRK Earnings Call
Q1 2024
0:00 / 0:00
---
MRK Sales Breakdown
45.91% Oncology
22.09% Vaccines
5.64% Hospital Acute Care
5.60% Diabetes
20.75% Other
---
MRK Stock 12 Month Forecast
Average Price Target
$147.40
▲(17.20% Upside)
Technical Analysis
Best Analysts Covering MRK
1 Year
1 Year Success Rate
18/21 ratings generated profit
1 Year Average Return
+15.05%
reiterated a buy rating 2 months ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +15.05% per trade.
---